Union européenne - suédois - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - graftförkastning - immunsuppressiva - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Union européenne - suédois - EMA (European Medicines Agency)

vetcare oy - medetomidine hydrochloride, vatinoxan hydrochloride - psykoleptika, hypnotika och lugnande medel - hundar - to provide restraint, sedation and analgesia during conduct of non-invasive, non-painful or mildly painful procedures and examinations intended to last no more than 30 minutes.

Union européenne - suédois - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 och 5. 1 för tillgänglig data på olika kombinationer).

Union européenne - suédois - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. - , trippel kombinationsterapi) som ett komplement till kost och motion hos patienter bristfälligt kontrollerad på deras maximal tolererad dos av metformin och en sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Union européenne - suédois - EMA (European Medicines Agency)

intervet international bv - indoxacarb, permethrin - permetrin, kombinationer, ectoparasiticides för utvärtes bruk, inkl. insektsmedel - hundar - behandling angrepp av loppor (ctenocephalides felis), produkten har ihållande insektsdödande effekt i upp till 4 veckor mot ctenocephalides felis. produkten har ihållande akaricid effekt i upp till 5 veckor mot ixodes ricinus och upp till 3 veckor mot rhipicephalus sanguineus. en behandling ger avstötande (anti-matande) aktivitet mot sandflugor (phlebotomus perniciosus) i upp till 3 veckor.

Union européenne - suédois - EMA (European Medicines Agency)

n.v. organon - desloratadin - rhinitis, allergic, perennial; urticaria; rhinitis, allergic, seasonal - antihistaminer för systemiskt bruk, - aerius är avsett för lindring av symptom i samband med allergisk rinit;urtikaria.

Union européenne - suédois - EMA (European Medicines Agency)

n.v. organon - desloratadin - rhinitis, allergic, perennial; urticaria; rhinitis, allergic, seasonal - antihistaminer för systemiskt bruk, - azomyr is indicated for the relief of symptoms associated with:allergic rhinitis (see section 5. 1)urticaria (see section 5.

Union européenne - suédois - EMA (European Medicines Agency)

teva pharma b.v. - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - kombinationer - clopidogrel / acetylsalicylsyra teva är indicerat för förebyggande av aterotrombotiska händelser hos vuxna patienter som redan tar både klopidogrel och acetylsalicylsyra (asa). clopidogrel/acetylsalicylsyra teva är en fast dos kombination läkemedel för fortsatt behandling i:icke‑st-segment höjd akuta koronara syndrom (instabil angina eller icke‑q‑våg hjärtinfarkt), inklusive patienter som genomgår en stent placering efter perkutan koronar interventionst segment höjd akut hjärtinfarkt i medicinskt behandlade patienter berättigade till trombolysbehandling.

Union européenne - suédois - EMA (European Medicines Agency)

sanofi-aventis groupe - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - antitrombotiska medel - akut kranskärlssjukdom syndromemyocardial infarkt.

Union européenne - suédois - EMA (European Medicines Agency)

krka, d.d., novo mesto - desloratadin - rhinitis, allergic, perennial; rhinitis, allergic, seasonal; urticaria - antihistaminer för systemiskt bruk, - dasselta är avsett för lindring av symptom i samband med allergisk rinit;urtikaria.